Inti Zlobec

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/833269/publications.pdf

Version: 2024-02-01

209 papers	14,382 citations	26630 56 h-index	24258 110 g-index
213 all docs	213 docs citations	213 times ranked	21164 citing authors

#	Article	IF	Citations
1	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	13.7	1,487
2	Towards the introduction of the â€˜Immunoscoreâ€™ in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	4.5	1,151
3	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	4.4	676
4	Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology, 2017, 30, 1299-1311.	5.5	652
5	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. Cell, 2020, 182, 1341-1359.e19.	28.9	464
6	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. European Journal of Cancer, 2013, 49, 2233-2242.	2.8	384
7	Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature, 2019, 573, 526-531.	27.8	320
8	High frequency of tumorâ€infiltrating FOXP3⁺ regulatory T cells predicts improved survival in mismatch repairâ€proficient colorectal cancer patients. International Journal of Cancer, 2010, 126, 2635-2643.	5.1	287
9	Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget, 2010, 1, 651-661.	1.8	272
10	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	8.1	227
11	Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. Journal of Clinical Pathology, 2007, 60, 1112-1116.	2.0	197
12	Tumor budding in colorectal cancerâ€”ready for diagnostic practice?. Human Pathology, 2016, 47, 4-19.	2.0	186
13	Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer. Cell Reports, 2017, 21, 3190-3204.	6.4	167
14	Tumour budding in solid cancers. Nature Reviews Clinical Oncology, 2021, 18, 101-115.	27.6	166
15	Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?. International Journal of Cancer, 2010, 126, 1256-1262.	5.1	156
16	Clinicopathological and protein characterization of BRAFâ€•and Kâ€RASâ€•mutated colorectal cancer and implications for prognosis. International Journal of Cancer, 2010, 127, 367-380.	5.1	136
17	ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nature Communications, 2013, 4, 2130.	12.8	136
18	Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. Clinical Cancer Research, 2018, 24, 4444-4454.	7.0	132

#	Article	IF	Citations
19	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	1.6	130
20	CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. Journal of Experimental Medicine, 2017, 214, 359-380.	8.5	125
21	Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Modern Pathology, 2008, 21, 1403-1412.	5.5	120
22	Loss of Raf-1 Kinase Inhibitor Protein Expression Is Associated With Tumor Progression and Metastasis in Colorectal Cancer. American Journal of Clinical Pathology, 2007, 127, 820-827.	0.7	119
23	Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Modern Pathology, 2013, 26, 295-301.	5.5	114
24	Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer. Immunity, 2013, 39, 1095-1107.	14.3	112
25	Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Human Pathology, 2013, 44, 697-705.	2.0	109
26	Invasive front of colorectal cancer: Dynamic interface ofpro-/anti-tumor factors. World Journal of Gastroenterology, 2009, 15, 5898.	3.3	107
27	The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. Mucosal Immunology, 2019, 12, 990-1003.	6.0	107
28	A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. Cell, 2019, 177, 572-586.e22.	28.9	107
29	Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology, 2011, 58, no-no.	2.9	104
30	Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. International Journal of Cancer, 2010, 127, 2569-2575.	5.1	99
31	HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker. Neoplasia, 2014, 16, 31-W15.	5.3	99
32	Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome. OncoImmunology, 2016, 5, e1106677.	4.6	99
33	The prognostic value of cytology and fluorescence in situ hybridization in the followâ€up of nonmuscleâ€invasive bladder cancer after intravesical Bacillus Calmetteâ€GuÃ©rin therapy. International Journal of Cancer, 2009, 124, 2899-2904.	5.1	98
34	Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 485-493.	2.8	94
35	High Myeloperoxidase Positive Cell Infiltration in Colorectal Cancer Is an Independent Favorable Prognostic Factor. PLoS ONE, 2013, 8, e64814.	2.5	92
36	Intratumoral budding as a potential parameter of tumor progression in mismatch repairâ€“proficient and mismatch repairâ€“deficient colorectal cancer patients. Human Pathology, 2011, 42, 1833-1840.	2.0	89

#	Article	IF	Citations
37	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leukemia and Lymphoma, 2010, 51, 199-212.	1.3	88
38	Tumor infiltration by FcÎ³RIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. International Journal of Cancer, 2011, 128, 2663-2672.	5.1	88
39	Fluorescence In Situ Hybridization in the Definitive Diagnosis of Malignant Mesothelioma in Effusion Cytology. Chest, 2010, 138, 137-144.	0.8	83
40	Role of KCNMA1 in Breast Cancer. PLoS ONE, 2012, 7, e41664.	2.5	83
41	HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology, 2012, 60, 397-404.	2.9	82
42	The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. OncoImmunology, 2016, 5, e1062966.	4.6	80
43	Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer, 2012, 12, 134.	2.6	77
44	Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with smallâ€volume or lowâ€grade prostate cancer. International Journal of Cancer, 2009, 124, 2116-2123.	5.1	76
45	The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. European Journal of Cancer, 2010, 46, 2304-2313.	2.8	76
46	Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology, 2012, 61, 562-575.	2.9	76
47	Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Modern Pathology, 2006, 19, 1236-1242.	5.5	72
48	Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 763-769.	2.8	70
49	Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Modern Pathology, 2012, 25, 1048-1053.	5.5	70
50	Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Modern Pathology, 2007, 20, 331-338.	5.5	69
51	Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression. Clinical Cancer Research, 2008, 14, 143-148.	7.0	69
52	Comprehensive analysis of CpG island methylator phenotype (CIMP)â€high, â€low, and â€negative colorectal cancers based on protein marker expression and molecular features. Journal of Pathology, 2011, 225, 336-343.	4.5	65
53	Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. Journal of Translational Medicine, 2013, 11, 104.	4.4	65
54	Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?. Frontiers in Medicine, 2018, 5, 234.	2.6	65

#	Article	IF	Citations
55	TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget, 2015, 6, 874-885.	1.8	64
56	High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Research and Treatment, 2015, 150, 363-371.	2.5	62
57	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. Clinical Colorectal Cancer, 2019, 18, e20-e38.	2.3	62
58	Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. European Journal of Cancer, 2007, 43, 1101-1107.	2.8	60
59	Multimarker phenotype predicts adverse survival in patients with lymph nodeâ€negative colorectal cancer. Cancer, 2008, 112, 495-502.	4.1	58
60	Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: A potential role for dysregulation of the transforming growth factor-Î² pathway. European Journal of Cancer, 2007, 43, 624-631.	2.8	57
61	Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. British Journal of Cancer, 2018, 119, 1244-1251.	6.4	57
62	Tumour budding in colorectal cancer: molecular rationale for clinical translation. Nature Reviews Cancer, 2018, 18, 203-204.	28.4	55
63	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology, 2021, 111, 883-894.	2.5	54
64	HOX D13 expression across 79 tumor tissue types. International Journal of Cancer, 2009, 125, 1532-1541.	5.1	53
65	GKAP Acts as a Genetic Modulator of NMDAR Signaling to Govern Invasive Tumor Growth. Cancer Cell, 2018, 33, 736-751.e5.	16.8	53
66	TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer. PLoS ONE, 2010, 5, e14282.	2.5	52
67	Assessment of Tumor Regression of Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. American Journal of Surgical Pathology, 2014, 38, 1551-1556.	3.7	52
68	Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma. Oncotarget, 2015, 6, 4190-4201.	1.8	52
69	Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Modern Pathology, 2006, 19, 1302-1309.	5.5	51
70	Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. International Journal of Cancer, 2014, 134, 2342-2351.	5.1	51
71	CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. Journal of Translational Medicine, 2014, 12, 81.	4.4	51
72	Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer. Human Pathology, 2019, 85, 145-151.	2.0	51

#	Article	IF	Citations
73	The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology, 2014, 64, 577-584.	2.9	49
74	VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer, 2005, 104, 2517-2521.	4.1	48
75	CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis. Leukemia Research, 2015, 39, 749-756.	0.8	48
76	Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study. BMC Cancer, 2015, 15, 160.	2.6	48
77	The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer. Oncotarget, 2017, 8, 70617-70629.	1.8	48
78	BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkinâ€™s lymphoma from primary mediastinal large Bâ€cell lymphoma. Histopathology, 2010, 56, 217-228.	2.9	47
79	A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies. Journal of Visualized Experiments, 2014, , 51893.	0.3	47
80	Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer. Journal of Translational Medicine, 2015, 13, 279.	4.4	47
81	The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. Anticancer Research, 2013, 33, 3053-9.	1.1	47
82	A Predictive Model of Rectal Tumor Response to Preoperative Radiotherapy Using Classification and Regression Tree Methods. Clinical Cancer Research, 2005, 11, 5440-5443.	7.0	46
83	RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis. Clinical Cancer Research, 2008, 14, 3798-3806.	7.0	46
84	Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer, 2009, 115, 4021-4029.	4.1	46
85	Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology, 2009, 55, 564-575.	2.9	46
86	ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World Journal of Gastroenterology, 2010, 16, 732.	3.3	46
87	Clinical Significance of Cell Cycleâ€“and Apoptosis-Related Markers in Biliary Tract Cancer. American Journal of Clinical Pathology, 2008, 130, 780-786.	0.7	45
88	Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer. Oncotarget, 2017, 8, 54604-54615.	1.8	45
89	Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World Journal of Gastroenterology, 2010, 16, 4823.	3.3	45
90	Local Recurrence in Mismatch Repairâ€“Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes. Clinical Cancer Research, 2008, 14, 3792-3797.	7.0	44

#	Article	IF	Citations
91	Expression Patterns of TNFÎ±, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 347-354.	1.3	44
92	Estrogen receptor Î² expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naÃ¯ve prostate cancer and are elevated in castration-resistant disease. Endocrine-Related Cancer, 2013, 20, 403-413.	3.1	43
93	Proper paraffin slide storage is crucial for translational research projects involving immunohistochemistry stains. Clinical and Translational Medicine, 2014, 3, 4.	4.0	43
94	Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome. Translational Research, 2015, 166, 207-217.	5.0	43
95	Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Human Pathology, 2011, 42, 1888-1896.	2.0	42
96	TREM-1 promotes intestinal tumorigenesis. Scientific Reports, 2017, 7, 14870.	3.3	41
97	CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clinical Epigenetics, 2018, 10, 120.	4.1	41
98	Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signalâ€“regulated kinase, and phosphorylated AKT in colorectal cancerâ€”A tissue microarrayâ€“based approachâ€†. Human Pathology, 2006, 37, 1022-1031.	2.0	40
99	Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology, 2011, 59, 482-495.	2.9	37
100	Tumor Budding in Upper Gastrointestinal Carcinomas. Frontiers in Oncology, 2014, 4, 216.	2.8	37
101	Prognostic impact of Î²-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. Journal of Clinical Pathology, 2012, 65, 996-1002.	2.0	36
102	Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers. Human Pathology, 2015, 46, 1573-1581.	2.0	36
103	Tumour budding and its clinical implications in gastrointestinal cancers. British Journal of Cancer, 2020, 123, 700-708.	6.4	36
104	Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients. Journal of Pathology: Clinical Research, 2017, 3, 58-70.	3.0	35
105	Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer. Histopathology, 2017, 70, 1044-1051.	2.9	32
106	TRPM4 is highly expressed in human colorectal tumor buds and contributes to proliferation, cell cycle, and invasion of colorectal cancer cells. Molecular Oncology, 2019, 13, 2393-2405.	4.6	32
107	Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 52-57.	1.7	31
108	Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas. Human Pathology, 2016, 52, 1-8.	2.0	31

#	Article	IF	Citations
109	Oncologic long-term outcomes of emergency versus elective resection for colorectal cancer. International Journal of Colorectal Disease, 2019, 34, 2091-2099.	2.2	31
110	Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater. Journal of Clinical Pathology, 2012, 65, 140-145.	2.0	30
111	Cytokeratinâ€based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience. Journal of Pathology: Clinical Research, 2017, 3, 171-178.	3.0	30
112	The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas. European Archives of Oto-Rhino-Laryngology, 2013, 270, 661-667.	1.6	29
113	Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. Frontiers in Oncology, 2013, 3, 265.	2.8	29
114	The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology, 2012, 61, 777-787.	2.9	28
115	A Multifactorial Histopathologic Score for the Prediction of Prognosis of Resected Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2014, 21, 915-921.	1.5	28
116	Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma. Human Pathology, 2019, 87, 18-27.	2.0	28
117	Improving tumor budding reporting in colorectal cancer: a Delphi consensus study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 459-469.	2.8	28
118	Systematic assessment of protein phenotypes characterizing highâ€grade tumour budding in mismatch repairâ€proficient colorectal cancer. Histopathology, 2010, 57, 233-243.	2.9	27
119	Tumour budding in pancreatic cancer revisited: validation of the <scp>ITBCC</scp> scoring system. Histopathology, 2018, 73, 137-146.	2.9	27
120	Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups. Modern Pathology, 2021, 34, 222-232.	5.5	27
121	Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC). Journal of Translational Medicine, 2013, 11, 311.	4.4	26
122	Prognostic Value of Cell Cycle and Apoptosis Regulatory Proteins in Mismatch Repairâ€“Proficient Colorectal Cancer. American Journal of Clinical Pathology, 2007, 127, 114-123.	0.7	25
123	Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma?. Human Pathology, 2008, 39, 1527-1534.	2.0	24
124	Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Human Pathology, 2010, 41, 70-78.	2.0	24
125	Novel biomarkers for the prediction of metastasis in colorectal cancer. Expert Opinion on Medical Diagnostics, 2013, 7, 137-146.	1.6	24
126	The ESRP1-GPR137 axis contributes to intestinal pathogenesis. ELife, 2017, 6, .	6.0	24

#	Article	IF	Citations
127	Cell Line Derived Xenograft Mouse Models Are a Suitable in vivo Model for Studying Tumor Budding in Colorectal Cancer. Frontiers in Medicine, 2019, 6, 139.	2.6	24
128	Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer. Radiation Oncology, 2015, 10, 240.	2.7	23
129	Validation of the International Tumor Budding Consensus Conference (ITBCC) 2016 recommendation in squamous cell carcinoma of the lungâ€"a single-center analysis of 354 cases. Modern Pathology, 2020, 33, 802-811.	5.5	23
130	LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. Journal of Personalized Medicine, 2021, 11, 749.	2.5	23
131	The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy. Cancer, 2006, 106, 284-286.	4.1	22
132	VE1 immunohistochemistry predictsBRAFV600E mutation status and clinical outcome in colorectal cancer. Oncotarget, 2015, 6, 41453-41463.	1.8	22
133	Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology, 2010, 42, 229-234.	0.6	21
134	Current opinion, status and future development of digital pathology in Switzerland. Journal of Clinical Pathology, 2020, 73, 341-346.	2.0	21
135	High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 741-748.	2.8	20
136	VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal patients. Modern Pathology, 2011, 24, 1404-1412.	5.5	20
137	Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells. Histopathology, 2015, 66, 715-725.	2.9	20
138	Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases. Cancer Immunology, Immunotherapy, 2017, 66, 777-786.	4.2	20
139	ATG12 deficiency leads to tumor cell oncosis owing to diminished mitochondrial biogenesis and reduced cellular bioenergetics. Cell Death and Differentiation, 2020, 27, 1965-1980.	11.2	20
140	Taking tumour budding to the next frontier â€" a post International Tumour Budding Consensus Conference (ITBCC) 2016 review. Histopathology, 2021, 78, 476-484.	2.9	20
141	Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin. Histopathology, 2015, 67, 464-473.	2.9	19
142	Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score. Histopathology, 2020, 76, 572-580.	2.9	19
143	Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1. Molecular Oncology, 2021, 15, 2782-2800.	4.6	19
144	Immunophenotyping analysis in invasive micropapillary carcinoma of the breast: Role of CD24 and CD44 isoforms expression. Breast, 2012, 21, 165-170.	2.2	18

#	Article	IF	Citations
145	PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential. European Journal of Cancer, 2016, 65, 80-90.	2.8	18
146	Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotypeâ€“genotype correlation. Journal of Pathology: Clinical Research, 2016, 2, 113-124.	3.0	18
147	Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth. ELife, 2020, 9, .	6.0	18
148	High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology, 2011, 58, 781-789.	2.9	17
149	Stratification and Prognostic Relevance of Jassâ€™s Molecular Classification of Colorectal Cancer. Frontiers in Oncology, 2012, 2, 7.	2.8	17
150	Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. Prostate, 2014, 74, 1647-1654.	2.3	17
151	Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer, 2010, 10, 93.	2.6	16
152	High Frequency of CD8 Positive Lymphocyte Infiltration Correlates with Lack of Lymph Node Involvement in Early Rectal Cancer. Disease Markers, 2014, 2014, 1-7.	1.3	16
153	Evaluation of Tumor Budding in Primary Colorectal Cancer and Corresponding Liver Metastases Based on H&E and Pancytokeratin Staining. Frontiers in Medicine, 2019, 6, 247.	2.6	16
154	Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 579-588.	2.8	14
155	Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups. Cancer, 2010, 116, 4474-4486.	4.1	14
156	DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 341-346.	2.8	14
157	DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells. Oncotarget, 2015, 6, 36774-36788.	1.8	14
158	Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. Lung Cancer, 2010, 68, 192-197.	2.0	13
159	Combined Histomorphologic and Immunohistochemical Phenotype to Predict the Presence of Vascular Invasion in Colon Cancer. Diseases of the Colon and Rectum, 2009, 52, 1114-1121.	1.3	12
160	Application of the 8th edition of the AJCC yTNM staging system shows improved prognostication in a single center cohort of esophageal carcinomas. Surgical Oncology, 2018, 27, 100-105.	1.6	12
161	Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lungâ€”A Single Center Analysis of 354 Cases. Frontiers in Medicine, 2019, 6, 196.	2.6	12
162	Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patients. European Journal of Cancer, 2020, 130, 139-145.	2.8	12

#	Article	IF	Citations
163	Refining the ITBCC tumor budding scoring system with a â€œzero-buddingâ€•category in colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1085-1090.	2.8	12
164	Update on the current opinion, status and future development of digital pathology in Switzerland in light of COVID-19. Journal of Clinical Pathology, 2022, 75, 687-689.	2.0	12
165	Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. OncoImmunology, 2017, 6, e1288330.	4.6	11
166	Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors. International Journal of Molecular Sciences, 2017, 18, 1640.	4.1	11
167	Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	11
168	Self-rule to multi-adapt: Generalized multi-source feature learning using unsupervised domain adaptation for colorectal cancer tissue detection. Medical Image Analysis, 2022, 79, 102473.	11.6	11
169	Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients. Oncotarget, 2014, 5, 4671-4682.	1.8	10
170	Role of tumor size in the pre-operative management of rectal cancer patients. BMC Gastroenterology, 2010, 10, 61.	2.0	9
171	Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?. Human Pathology, 2011, 42, 702-709.	2.0	9
172	Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer. Modern Pathology, 2022, 35, 240-248.	5.5	9
173	Classification of colorectal tissue images from high throughput tissue microarrays by ensemble deep learning methods. Scientific Reports, 2021, 11, 2371.	3.3	9
174	Prospective Validation of Facial Nerve Monitoring to Prevent Nerve Damage During Robotic Drilling. Frontiers in Surgery, 2019, 6, 58.	1.4	8
175	Investigating new serological and tissue markers for the followâ€up of patients operated for alveolar echinococcosis. Parasite Immunology, 2021, 43, e12827.	1.5	8
176	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. SSRN Electronic Journal, 0, , .	0.4	8
177	The battle for prognosis at the invasive front of colorectal cancer. EBioMedicine, 2020, 58, 102918.	6.1	7
178	Combined Simplified Molecular Classification of Gastric Adenocarcinoma, Enhanced by Lymph Node Status: An Integrative Approach. Cancers, 2021, 13, 3722.	3.7	7
179	Tutorial: methods for three-dimensional visualization of archival tissue material. Nature Protocols, 2021, 16, 4945-4962.	12.0	7
180	Rhesus Macaque CODEX Multiplexed Immunohistochemistry Panel for Studying Immune Responses During Ebola Infection. Frontiers in Immunology, 2021, 12, 729845.	4.8	7

#	Article	IF	Citations
181	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC Cancer, 2022, 22, 394.	2.6	7
182	Towards a national strategy for digital pathology in Switzerland. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 647-652.	2.8	7
183	KIT, PDGFRÎ± and EGFR analysis in nephroblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 637-650.	2.8	6
184	Impact of the Microenvironment on Tumour Budding in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2018, 1110, 101-111.	1.6	6
185	Tumour budding and CD8⁺ T cells: â€˜attackersâ€™ and â€˜defendersâ€™ in rectal cancer with and without neoadjuvant chemoradiotherapy. Histopathology, 2021, 78, 1009-1018.	2.9	6
186	Prediction of outcome in patients with lowâ€grade squamous intraepithelial lesions by fluorescence in situ hybridization analysis of human papillomavirus, TERC, and MYC. Cancer Cytopathology, 2013, 121, 423-431.	2.4	5
187	Macroscopy predicts tumor progression in gastric cancer: A retrospective patho-historical analysis based on Napoleon Bonaparte's autopsy report. Digestive and Liver Disease, 2016, 48, 1378-1385.	0.9	5
188	Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type. Oncology Reports, 2017, 38, 2394-2400.	2.6	5
189	Classification of Intestinal Gland Cell-Graphs Using Graph Neural Networks. , 2021, , .		5
190	RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. Pathology Research and Practice, 2021, 223, 153486.	2.3	5
191	Tumor budding in the clinical management of colon and rectal cancer. Colorectal Cancer, 2014, 3, 387-403.	0.8	4
192	Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. Sarcoma, 2021, 2021, 1-12.	1.3	4
193	An Effective Deep Learning Architecture Combination for Tissue Microarray Spots Classification of H&E Stained Colorectal Images. , 2020, , .		4
194	Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients. International Journal of Surgical Oncology, 2012, 2012, 1-6.	0.6	3
195	Editorial: Computational Pathology. Frontiers in Medicine, 2020, 7, 245.	2.6	3
196	Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 719-726.	2.8	3
197	Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types.. Journal of Clinical Oncology, 2021, 39, 3118-3118.	1.6	3
198	Standardization of whole slide image morphologic assessment with definition of a new application: Digital slide dynamic morphometry. Journal of Pathology Informatics, 2011, 2, 48.	1.7	3

#	Article	IF	Citations
199	Tissue Microarray Technology for Molecular Applications: Investigation of Cross-Contamination between Tissue Samples Obtained from the Same Punching Device. Microarrays (Basel, Switzerland), 2015, 4, 188-195.	1.4	2
200	Gene Signatures in Colorectal Cancer. , 2012, , 115-136.		2
201	A Digital Pathology-Based Shotgun-Proteomics Approach to Biomarker Discovery in Colorectal Cancer. Journal of Pathology Informatics, 2019, 10, 40.	1.7	2
202	Assessing downgrading of locally advanced rectal cancer after chemo-radiotherapy. European Journal of Cancer, 2011, 47, 1125-1126.	2.8	1
203	Next-generation tissue microarrays (ngTMA) in translational research. European Journal of Molecular and Clinical Medicine, 2017, 2, 58.	0.1	1
204	Molecular and Histological Profiling Reveals an Innate-Shaped Immune Microenvironment in Solitary Juvenile Polyps. Clinical and Translational Gastroenterology, 2021, 12, e00361.	2.5	1
205	S2041 Biological Marker Expression Selects a Subgroup of Early Rectal Cancer Patients for Pre-Operative Therapy. Gastroenterology, 2008, 134, A-303.	1.3	0
206	S2040 Tumor Infiltrating Lymphocytes and RHAMM Expression Predict Prognosis in Patients with Rectal Cancer. Gastroenterology, 2008, 134, A-303.	1.3	0
207	Tu1868 PTEN Loss in the Neoplastic Stroma of Pancreatic Ductal Adenocarcinoma (PDAC) Is a Strong Predictor of Distant Metastasis. Gastroenterology, 2013, 144, S-868.	1.3	0
208	Prognostic Significance of Protein Markers in Colorectal Cancer Stratified by Mismatch Repair Status. , 2009, , 227-240.		0
209	Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer.. Journal of Clinical Oncology, 2020, 38, 227-227.	1.6	0